Abstract
We compared adjuvant chemotherapy-related myocardial damage by antimyosin scintigraphy in patients who received either nine cycles of FEC (fluorouracil, epirubicin and cyclophosphamide) where the doses of epirubicin and cyclophosphamide were escalated according to the leucocyte nadir (group I, n = 14), three cycles of FEC followed by high-dose chemotherapy with alkylating agents (CTCb) given with the support of peripheral blood stem cell transplantation (group II, n = 14), or six cycles of standard intravenous CMF (cyclophosphamide, methotrexate and fluorouracil; group III, n = 8). The cardiac uptake of In-111-antimyosin-Fab (R11D10) antibody was measured and the heart-to-lung ratio (HLR) calculated 8–36 months after the last dose of chemotherapy. Cardiac antimyosin antibody uptake was considerably higher among patients treated with nine cycles of dose-escalated FEC than among those who were treated with three cycles of FEC and high-dose CTCb (HLR, median 1.98; range 1.36–2.24 vs median 1.51; range 1.20–1.82;P< 0.001), or those treated with CMF (median 1.44; range 1.15–1.68;P< 0.001). The difference between groups II and III was not significant (P> 0.1). A linear association was found between the cumulative dose of epirubicin and the cardiac antimyosin uptake (P< 0.001). We conclude that subclinical cardiac damage caused by three cycles of conventional-dose FEC followed by one cycle of high-dose CTCb chemotherapy is small as compared with the damage caused by dose-escalated FEC. © 2000 Cancer Research Campaign
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Antman KH, Rowlings PA, Vaughan WP, Pelz CJ, Fay JW, Fields KK, Freytes CO, Gale RP, Hillner BE, Holland HK, Kennedy MJ, Klein JP, Lazarus HM, McCarthy PJ Jr, Saez R, Spitzer G, Stadtmauer EA, Williams SF, Wolff S, Sobocinski KA, Armitage JO and Horowitz MM (1997) High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America. J Clin Oncol 15: 1870–1879
Astorri E, Contini GA, Fiorina P, Gavaruzzi D and Fesani F (1996) Myocardial indium-111 antimyosin uptake after uncomplicated coronary artery bypass surgery. Int J Cardiol 55: 239–244
Ballester M, Marti V, Carrio I, Obrador D, Moya C, Pons-Llado G, Berna L, Lamich R, Aymat MR, Barbanoj M, Guardia J, Carreras F, Udina C, Auge JM, Marrugat J, Permanyer G and Caralps-Riera JM (1997 a) Spectrum of alcohol-induced myocardial damage detected by indium-111-labeled monoclonal antimyosin antibodies. J Am Coll Cardiol 29: 160–167
Ballester M, Marti V, Obrador D, Carrio I and Marrugat J (1997 b) Role of 111 In-monoclonal antimyosin antibodies in risk stratification of patients with dilated cardiomyopathy referred for heart transplantation. Transplant P 29: 589–591
Bengel FM, Feistel H, Moshage W, Bachman K and Wolf F (1997) Myocardial damage assessed by indium-111-antimyosin: correlation with persistent enteroviral ribonucleic acid in dilated cardiomyopathy. Eur J Nucl Med 24: 1128–1131
Bergh J, Wiklund T, Erikstein B, Fornander T, Bengtsson NO, Malmstrom P, Kellokumpu-Lehtinen P, Anker G, Bennmarker H and Wilking N (1998) Dosage of adjuvant G-CSF (filgrastim); supported FEC polychemotherapy based on equivalent haematological toxicity in high-risk breast cancer patients. Ann Oncol 9: 403–411
Bhattacharya S and Lahiri A (1991) Clinical role of indium-111 antimyosin imaging. Eur J Nucl Med 18: 889–895
Booser DJ and Hortobagyi GN (1994) Anthracycline antibiotics in cancer therapy. Focus on drug resistance. Drugs 47: 223–228
Braverman AC, Antin JH, Plappert MT, Cook EF and Lee RT (1991) Cyclophosphamide cardiotoxicity in bone marrow transplantation: a prospective evaluation of new regimens. J Clin Oncol 9: 1215–1223
Carrio I, Lopez-Pousa A, Estorch M, Duncker D, Berna L, Torres G and de Andres L (1993) Detection of doxorubicin cardiotoxicity in patients with sarcomas by indium-111-antimyosin monoclonal antibody studies. J Nucl Med 34: 1503–1507
Carrio I, Estorch M, Berna L, Lopez-Pousa J, Tabernero J and Torres G (1995) Indium-111-antimyosin and iodine-123-MIBG studies in early assessment of doxorubicin cardiotoxicity. J Nucl Med 36: 2044–2049
Dardir MD, Ferrans VJ, Mikhael YS, el-Grindy MS, el-Aasar AB, el-Zawahry Alling DW, Banks SM and el-Mawla NG (1989) Cardiac morphologic and functional changes induced by epirubicin chemotherapy. J Clin Oncol 7: 947–958
Early Breast Cancer Trialists’ Collaborative Group (1998) Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 352: 930–942
Estorch M, Carrio I, Martinez-Duncker D, Berna L, Torres G, Alanso C and Ojeda B (1993) Myocyte cell damage after administration of doxorubicin or mitoxantrone in breast cancer patients assessed by indium 111 antimyosin monoclonal antibody studies. J Clin Oncol 11: 1264–1268
Fraiser LH, Kanekal S and Kehrer JP (1991) Cyclophosphamide toxicity. Characterising and avoiding the problem. Drugs 42: 781–795
Goldberg MA, Antin JH, Guinan EC and Rappeport JM (1986) Cyclophosphamide cardiotoxicity: an analysis of dosing as a risk factor. Blood 68: 1114–1118
Grathwohl A, Hermans J and Baldomero H (1997) Blood and marrow transplantation activity in Europe 1995. Bone Marrow Transpl 19: 407–419
Green M (1998) Anthracycline cardiotoxicity, no longer an issue?. Ann Oncol 9: 691–693
Jain KK, Casper ES, Geller NL, Hakes TB, Kaufman RJ, Currie V, Schwartz W, Cassidy C, Petroni GR, Young CW and Wittes RE (1985) A prospective randomized comparison of epirubicin and doxorubicin in patients with advanced breast cancer. J Clin Oncol 3: 818–826
Jensen BV, Nielsen SL and Skovsgaard T (1996) Treatment with angiotensin-converting-enzyme inhibitor for epirubicin-induced dilated cardiomyopathy. Lancet 347: 297–299
Kairemo KJA, Wiklund TA, Liewendahl K, Miettinen M, Heikkonen JJ, Virkkunen P, Aronen HJ and Blomqvist CP (1980) Imaging of soft-tissue sarcomas with Indium-111-labelled monoclonal antimyosin fab fragments. J Nucl Med 31: 23–31
Kairemo KJA, Blomqvist CP and Miettinen M (1996) Cardiac myxomas. N Engl J Med 334: 1407–1408
Legha S, Benjamin RS and Mackay B (1982) Reduction of doxorubicin toxicity by prolonged intravenous infusion. Ann Intern Med 96: 133–139
Lopez M, Vici P, Di Lauro L, Conti F, Paoletti G, Ferraironi A, Sciuto R, Giannarelli D and Maini CL (1998) Randomized prospective clinical trial of high-dose epirubicin and dexrazoxane in patients with advanced breast cancer and soft tissue sarcomas. J Clin Oncol 16: 86–92
Nielsen D, Jensen JB, Dombernowsky P, Munck O, Fogh J, Brynjolf I, Havsteen H and Hansen M (1990) Epirubicin cardiotoxicity: a study of 135 patients with advanced breast cancer. J Clin Oncol 8: 1806–1810
Peters WP (1996) High-dose chemotherapy for breast cancer. Diseases of the Breast, 735–743, Lippincott-Raven: Philadelphia
Schutz A, Breuer M and Kemkes BM (1997) Antimyosin antibodies in cardiac rejection. Ann Thorac Surg 63: 578–581
Torti FM, Bristow MM, Lum BL, Carter SK, Howes AE, Aston DA, Brown BW Jr, Hannigan JF Jr, Meyers FJ and Mitchell EP (1986) Cardiotoxicity of epirubicin and doxorubicin: assessment by endomyocardial biopsy. Cancer Res 46: 3722–3727
Valdes ORA, Bokkel Huinink WW, Hoeve RF, van Tinteren H, Bruning PF, van Vlies B and Hoefnagel CA (1994) Usefulness of indium-111 antimyosin scintigraphy in confirming myocardial injury in patients with anthracycline-associated left ventricular dysfunction. Ann Oncol 5: 617–622
Verna E, Ceriani L, Casucci R, Repetto S, Roncari G and Binaghi G (1995) Myocardial uptake of indium-111 antimyosin after coronary angioplasty. Relationship with the total burden of ischaemia. Eur Heart J 16: 478–484
Yamada T, Matsumori A, Watanabe Y, Tamaki N, Yonekura Y, Endo K, Konishi J and Kawai C (1990) Pharmacokinetics of indium-111-labeled antimyosin monoclonal antibody in murine experimental viral myocarditis. J Am Coll Cardiol 16: 1280–1286
Yamada T, Tamaki N, Morishima S, Konishi J, Yoshida A and Matsumori A (1992) Time course of myocardial infarction evaluated by indium-111-antimyosin monoclonal antibody scintigraphy: clinical implications and prognostic value. J Nucl Med 33: 1501–1508
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Erselcan, T., Kairemo, K., Wiklund, T. et al. Subclinical cardiotoxicity following adjuvant dose-escalated FEC, high-dose chemotherapy, or CMF in breast cancer. Br J Cancer 82, 777–781 (2000). https://doi.org/10.1054/bjoc.1999.0998
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.1999.0998
Keywords
This article is cited by
-
Comprehensive review on cardio-oncology: Role of multimodality imaging
Journal of Nuclear Cardiology (2017)
-
Combination chemotherapy with cyclophosphamide, epirubicin and 5-fluorouracil causes trabecular bone loss, bone marrow cell depletion and marrow adiposity in female rats
Journal of Bone and Mineral Metabolism (2016)
-
Impact of Mindfulness-Based Stress Reduction (MBSR) on attention, rumination and resting blood pressure in women with cancer: A waitlist-controlled study
Journal of Behavioral Medicine (2012)
-
Three versus six months of exercise training in breast cancer survivors
Breast Cancer Research and Treatment (2010)
-
Cardiac toxicity of high-dose chemotherapy
Bone Marrow Transplantation (2005)